Antibody–drug conjugate explained

Antibody–drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer.[1] Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells. As of 2019, some 56 pharmaceutical companies were developing ADCs.[2]

ADCs are complex molecules composed of an antibody linked to a biologically active cytotoxic (anticancer) payload or drug.[3] Antibody–drug conjugates are an example of bioconjugates and immunoconjugates.

ADCs combine the targeting properties of monoclonal antibodies with the cancer-killing capabilities of cytotoxic drugs, designed to discriminate between healthy and diseased tissue.[4] [5]

Mechanism of action

An anticancer drug is coupled to an antibody that targets a specific tumor antigen (or protein) that, ideally, is only found in or on tumor cells. Antibodies attach themselves to the antigens on the surface of cancerous cells. The biochemical reaction that occurs upon attaching triggers a signal in the tumor cell, which then absorbs, or internalizes, the antibody together with the linked cytotoxin. After the ADC is internalized, the cytotoxin kills the cancer.[6] Their targeting ability was believed to limit side effects for cancer patients and to give a wider therapeutic window than other chemotherapeutic agents, although this promise hasn't yet been realized in the clinic.[7]

ADC technologies have been featured in many publications,[8] [9] including scientific journals.

History

The idea of drugs that would target tumor cells and ignore others was conceived in 1900 by German Nobel laureate Paul Ehrlich; he described the drugs as a "magic bullet" due to their targeting properties.

In 2001 Pfizer/Wyeth's drug Gemtuzumab ozogamicin (trade name: Mylotarg) was approved based on a study with a surrogate endpoint, through the accelerated approval process. In June 2010, after evidence accumulated showing no evidence of benefit and significant toxicity, the U.S. Food and Drug Administration (FDA) forced the company to withdraw it.[10] It was reintroduced into the US market in 2017.[11]

Brentuximab vedotin (trade name: Adcetris, marketed by Seattle Genetics and Millennium/Takeda)[12] was approved for relapsed HL and relapsed systemic anaplastic large-cell lymphoma (sALCL)) by the FDA on August 19, 2011 and received conditional marketing authorization from the European Medicines Agency in October 2012.

Trastuzumab emtansine (ado-trastuzumab emtansine or T-DM1, trade name: Kadcyla, marketed by Genentech and Roche) was approved in February 2013 for the treatment of people with HER2-positive metastatic breast cancer (mBC) who had received prior treatment with trastuzumab and a taxane chemotherapy.[13] [14]

The European Commission approved Inotuzumab ozogamicin[15] as a monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) on June 30, 2017 under the trade name Besponsa® (Pfizer/Wyeth),[16] followed on August 17, 2017 by the FDA.[17]

The first immunology antibody–drug conjugate (iADC), ABBV-3373,[18] showed an improvement in disease activity in a Phase 2a study of patients with rheumatoid arthritis and a study with the second iADC, ABBV-154[19] [20] to evaluate adverse events and change in disease activity in participants treated with subcutaneous injection of ABBV-154 is ongoing.

In July 2018, Daiichi Sankyo Company, Limited and Glycotope GmbH have inked a pact regarding the combination of Glycotope's investigational tumor-associated TA-MUC1 antibody gatipotuzumab and Daiichi Sankyo's proprietary ADC technology for developing gatipotuzumab antibody drug conjugate.[21]

In 2019 AstraZeneca agreed to pay up to US$6.9 billion to jointly develop DS-8201 with Japan's Daiichi Sankyo. It is intended to replace Herceptin for treating breast cancer. DS8201 carries eight payloads, compared to the usual four.

Commercial products

Thirteen ADCs have received market approval by the FDA – all for oncotherapies. Belantamab mafodotin is in the process of being withdrawn from US marketing.

FDA Approved ADCs!Drug!Trade name!Maker!Condition
Gemtuzumab ozogamicinMylotargPfizer/Wyethrelapsed acute myelogenous leukemia (AML)
Brentuximab vedotinAdcetrisSeattle Genetics, Millennium/TakedaHodgkin lymphoma (HL) and systemic anaplastic large-cell lymphoma (ALCL)
Trastuzumab emtansineKadcylaGenentech, RocheHER2-positive metastatic breast cancer (mBC) following treatment with trastuzumab and a maytansinoid
Inotuzumab ozogamicinBesponsaPfizer/Wyethrelapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia
Polatuzumab vedotinPolivyGenentech, Rocherelapsed or refractory diffuse large B-cell lymphoma (DLBCL)[22]
Enfortumab vedotinPadcevAstellas/Seattle Geneticsadult patients with locally advanced or metastatic urothelial cancer who have received a PD-1 or PD-L1 inhibitor, and a Pt-containing therapy[23]
Trastuzumab deruxtecanEnhertuAstraZeneca/Daiichi Sankyoadult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens[24]
Sacituzumab govitecanTrodelvyImmunomedicsadult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for patients with relapsed or refractory metastatic disease[25]
Belantamab mafodotinBlenrepGlaxoSmithKlinemultiple myeloma patients whose disease has progressed despite prior treatment with an immunomodulatory agent, proteasome inhibitor and anti-CD38 antibody[26]
Moxetumomab pasudotoxLumoxitiAstraZenecarelapsed or refractory hairy cell leukemia (HCL)
Loncastuximab tesirineZynlontaADC Therapeuticsrelapsed or refractory large B-cell lymphoma (including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma) after two or more lines of systemic therapy
Tisotumab vedotin-tftvTivdakSeagen Inc, Genmabadult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy[27]
Mirvetuximab soravtansineElahereImmunoGentreatment of adult patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens

Components of an ADC

An antibody–drug conjugate consists of 3 components:[28] [29]

Payloads

Many of the payloads for oncology ADCs (oADC) are natural product based [31] with some making covalent interactions with their target.[32] Payloads include the microtubulin inhibitors monomethyl auristatin E (MMAE),[33] monomethyl auristatin F (MMAF)[34] and mertansine,[35] DNA binder calicheamicin[36] and topoisomerase 1 inhibitors SN-38[37] and exatecan[38] resulting in a renaissance for natural product total synthesis.[39] Glucocorticoid receptor modulators (GRMs) represent to most active payload class for iADCs. Approaches releasing marketed GRM molecules such as dexamethasone[40] [41] and budesonide[42] have been developed. Modified GRM molecules[43] [44] have also been developed that enable the attachment of the linker with the term ADCidified describing the medicinal chemistry process of payload optimization to facilitate linker attachment.[45] Alternatives to small molecule payloads have also been investigated, for example, siRNA.[46]

Linkers

A stable link between the antibody and cytotoxic (anti-cancer) agent is a crucial aspect of an ADC.[47] A stable ADC linker ensures that less of the cytotoxic payload falls off before reaching a tumor cell, improving safety, and limiting dosages.

Linkers are based on chemical motifs including disulfides, hydrazones or peptides (cleavable), or thioethers (noncleavable). Cleavable and noncleavable linkers were proved to be safe in preclinical and clinical trials. Brentuximab vedotin includes an enzyme-sensitive cleavable linker that delivers the antimicrotubule agent monomethyl auristatin E or MMAE, a synthetic antineoplastic agent, to human-specific CD30-positive malignant cells. MMAE inhibits cell division by blocking the polymerization of tubulin. Because of its high toxicity MMAE cannot be used as a single-agent chemotherapeutic drug. However, MMAE linked to an anti-CD30 monoclonal antibody (cAC10, a cell membrane protein of the tumor necrosis factor or TNF receptor) was stable in extracellular fluid. It is cleavable by cathepsin and safe for therapy. Trastuzumab emtansine is a combination of the microtubule-formation inhibitor mertansine (DM-1) and antibody trastuzumab that employs a stable, non-cleavable linker.

The availability of better and more stable linkers has changed the function of the chemical bond. The type of linker, cleavable or noncleavable, lends specific properties to the cytotoxic drug. For example, a non-cleavable linker keeps the drug within the cell. As a result, the entire antibody, linker and cytotoxic (anti-cancer) agent enter the targeted cancer cell where the antibody is degraded into an amino acid. The resulting complex – amino acid, linker and cytotoxic agent – is considered to be the active drug. In contrast, cleavable linkers are detached by enzymes in the cancer cell. The cytotoxic payload can then escape from the targeted cell and, in a process called "bystander killing", attack neighboring cells.[48]

Another type of cleavable linker, currently in development, adds an extra molecule between the cytotoxin and the cleavage site. This allows researchers to create ADCs with more flexibility without changing cleavage kinetics. Researchers are developing a new method of peptide cleavage based on Edman degradation, a method of sequencing amino acids in a peptide.[49] Also under development are site-specific conjugation (TDCs) and novel conjugation techniques[50] [51] to further improve stability and therapeutic index, α emitting immunoconjugates,[52] antibody-conjugated nanoparticles[53] and antibody-oligonucleotide conjugates.[54]

Anything Drug Conjugates

As the antibody–drug conjugate field has matured, a more accurate definition of ADC is now Anything-Drug Conjugate. Alternatives for the antibody targeting component now include multiple smaller antibody fragments[55] like diabodies,[56] Fab,[57] scFv,[58] and bicyclic peptides.[59]

Research

Non-natural amino acids

The first generation uses linking technologies that conjugate drugs non-selectively to cysteine or lysine residues in the antibody, resulting in a heterogeneous mixture. This approach leads to suboptimal safety and efficacy and complicates optimization of the biological, physical and pharmacological properties.[60] Site-specific incorporation of unnatural amino acids generates a site for controlled and stable attachment. This enables the production of homogeneous ADCs with the antibody precisely linked to the drug and controlled ratios of antibody to drug, allowing the selection of a best-in-class ADC. An Escherichia coli-based open cell-free synthesis (OCFS) allows the synthesis of proteins containing site-specifically incorporated non-natural amino acids and has been optimized for predictable high-yield protein synthesis and folding. The absence of a cell wall allows the addition of non-natural factors to the system to manipulate transcription, translation and folding to provide precise protein expression modulation.[61]

Other disease areas

The majority of ADCs under development or in clinical trials are for oncological and hematological indications.[62] This is primarily driven by the inventory of monoclonal antibodies, which target various types of cancer. However, some developers are looking to expand the application to other important disease areas.[63] [64] [65]

See also

Industry Conferences

Notes and References

  1. Hamilton GS . Antibody–drug conjugates for cancer therapy: The technological and regulatory challenges of developing drug-biologic hybrids . Biologicals . 43 . 5 . 318–32 . September 2015 . 26115630 . 10.1016/j.biologicals.2015.05.006 .
  2. Web site: Drug to replace chemotherapy may reshape cancer care. Matsuyama. Kanoko . vanc . 2019-06-11. BNN Bloomberg. 2019-06-14.
  3. Web site: Antibody-Drug Conjugates Stage a Comeback. March 9, 2010. Patricia F. . Fitzpatrick-Dimond . vanc . GEN: Genetic Engineering and Biotechnology News.
  4. DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L, Kunz A, Hamann PR, Gorovits B, Udata C, Moran JK, Popplewell AG, Stephens S, Frost P, Damle NK . 6 . Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies . Blood . 103 . 5 . 1807–14 . March 2004 . 14615373 . 10.1182/blood-2003-07-2466 . 17543492 . free .
  5. Mullard A . Maturing antibody–drug conjugate pipeline hits 30 . Nature Reviews. Drug Discovery . 12 . 5 . 329–32 . May 2013 . 23629491 . 10.1038/nrd4009 . 28757488 .
  6. Chari RV, Martell BA, Gross JL, Cook SB, Shah SA, Blättler WA, McKenzie SJ, Goldmacher VS . 6 . Immunoconjugates containing novel maytansinoids: promising anticancer drugs . Cancer Research . 52 . 1 . 127–31 . January 1992 . 1727373 .
  7. Colombo R, Jamie RR . The therapeutic window of antibody drug conjugates: A dogma in need of revision . Cancer Cell . 40 . 11 . 1255-1263 . November 2022 . 36240779 . 10.1016/j.ccell.2022.09.016 .
  8. Web site: A One-Two Punch . Pollack A . May 31, 2012 . The New York Times .
  9. Web site: Ferrying a Drug Into a Cancer Cell . The New York Times. June 3, 2012.
  10. Web site: FDA: Pfizer Voluntarily Withdraws Cancer Treatment Mylotarg from U.S. Market . U.S. Food and Drug Administration . https://web.archive.org/web/20170118091738/https://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm216458.htm . 2017-01-18 .
  11. Web site: Approved Drugs > FDA Approves Gemtuzumab Ozogamicin for CD33-positive AML . fda.gov. U.S. Food and Drug Administration. 1 September 2017. 6 September 2017. Silver Spring, USA.
  12. Web site: Brentuximab vedotin (SGN35) ]. ADC Review/Journal of Antibody-drug Conjugates .
  13. Web site: FDA Approves Genentech's Kadcyla® (Ado-Trastuzumab Emtansine), the First Antibody-Drug Conjugate for Treating Her2-Positive Metastatic Breast Cancer . Genentech . 2013-06-30 . 2019-06-17 . https://web.archive.org/web/20190617124418/https://www.gene.com/media/press-releases/14347/2013-02-22/fda-approves-genentechs-kadcyla-ado-tras . dead .
  14. Web site: Ado-trastuzumab emtansine . U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. .
  15. Web site: Inotuzumab ozogamicin (drug description) . ADC Review/Journal of Antibody-drug Conjugates .
  16. BESPONSA® Approved in the EU for Adult Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia . 30 June 2017 .
  17. Web site: U.S. FDA Approves Inotuzumab Ozogamicin for Treatment of Patients with R/R B-cell precursor Acute Lymphoblastic Leukemia . ADC Review/Journal of Antibody-drug Conjugates . August 17, 2017 .
  18. Hobson AD, McPherson MJ, Hayes ME, Goess C, Li X, Zhou J, Wang Z, Yu Y, Yang J, Sun L, Zhang Q, Qu P, Yang S, Hernandez A Jr, Bryant SH, Mathieu SL, Bischoff AK, Fitzgibbons J, Santora LC, Wang L, Wang L, Fettis MM, Li X, Marvin CC, Wang Z, Patel MV, Schmidt DL, Li T, Randolph JT, Henry RF, Graff C, Tian Y, Aguirre AL, Shrestha A . Discovery of ABBV-3373, an Anti-TNF Glucocorticoid Receptor Modulator Immunology Antibody Drug Conjugate . Journal of Medicinal Chemistry . Dec 2022 . 36394224 . 10.1021/acs.jmedchem.2c01579 . 65 . 23 . 15893–15934.
  19. Hobson AD, Xu J, Marvin CC, McPherson MJ, Hollmann M, Gattner M, Dzeyk K, Fettis MM, Bischoff AK, Wang L, Fitzgibbons J, Wang L, Salomon P, Hernandez A Jr, Jia Y, Sarvaiya H, Goess CA, Mathieu SL, Santora LC . Optimization of Drug-Linker to Enable Long-term Storage of Antibody-Drug Conjugate for Subcutaneous Dosing . Journal of Medicinal Chemistry . Jul 2023 . 37379257 . 10.1021/acs.jmedchem.3c00794 . 66 . 13 . 9161–9173.
  20. Hobson AD, Xu J, Welch DS, Marvin CC, McPherson MJ, Gates B, Liao X, Hollmann M, Gattner MJ, Dzeyk K, Sarvaiya H, Shenoy VM, Fettis MM, Bischoff AK, Wang L, Santora LC, Wang L, Fitzgibbons J, Salomon P, Hernandez A Jr, Jia Y, Goess CA, Mathieu SL, Bryant SH, Larsen ME, Cui B, Tian Y . Discovery of ABBV-154, an anti-TNF Glucocorticoid Receptor Modulator Immunology Antibody-Drug Conjugate (iADC) . Journal of Medicinal Chemistry . Sep 2023 . 37656698 . 10.1021/acs.jmedchem.3c01174 . 66 . 17 . 12544–12558.
  21. Web site: Antibody Drug Conjugate Market Size, Share, Trends, Growth Analysis Report, Application Immunotherapy, Business Opportunity Industry, Future Trends Forecast - 2023 |. September 24, 2019.
  22. Web site: FDA approves first chemoimmunotherapy regimen for patients with relapsed or refractory diffuse large B-cell lymphoma. Commissioner. Office of the. 2019-06-10. FDA. en. 2019-06-14.
  23. Web site: FDA grants accelerated approval to enfortumab vedotin-ejfv for metastatic urothelial cancer. 2019-12-18. FDA. en. 2020-01-03.
  24. Web site: FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies. 2019-12-20. FDA. en. 2020-01-03.
  25. Web site: FDA Approves New Therapy for Triple Negative Breast Cancer That Has Spread, Not Responded to Other Treatments. 2020-04-22. FDA. en. 2020-04-24.
  26. Web site: FDA granted accelerated approval to belantamab mafodotin-blmf for multiple myeloma. 2020-08-06. FDA. en. 2020-08-06.
  27. News: Seagen and Genmab Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer. Businesswire.
  28. Beck A, Goetsch L, Dumontet C, Corvaïa N . Advances in Antibody-Drug Conjugate Design: Current Clinical Landscape and Future Innovations . SLAS Discov . 25 . 8 . 843–868 . March 2020 . 28303026 . 10.1177/2472555220912955 . 214591000 . free .
  29. Khongorzul P, Ling CJ, Khan FU, Ihsan AW, Zhang J. Antibody-Drug Conjugates: A Comprehensive Review . Mol Cancer Res . 18 . 1 . 3–19 . January 2020 . 31659006 . 10.1158/1541-7786.MCR-19-0582 . 204952454 .
  30. Kang MS, Kong T, Khoo J, Loh TP . Recent developments in chemical conjugation strategies targeting native amino acids in proteins and their applications in antibody–drug conjugates . Chem Sci . 12 . 41 . 13613–13647. October 2021 . 34760149 . 10.1039/D1SC02973H . 8549674 . 240811966 . free .
  31. Gromek SM, Balunas MJ . Natural products as exquisitely potent cytotoxic payloads for antibody- drug conjugates . Curr Top Med Chem . 14 . 24 . 2822–2834 . 2015 . 30879472 . 10.2174/1568026615666141208111253 .
  32. Vasudevan A, Argiriadi MA, Baranczak A, Friedman MM, Gavrilyuk J, Hobson AD, Hulce JJ, Osman S, Wilson NS . Chapter One - Covalent binders in drug discovery . Progress Med Chem . 58 . 2822–2834 . March 2019 . 24 . 25487009 . 10.1016/bs.pmch.2018.12.002 . 81979586 .
  33. Senter PD, Sievers EL . The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma . Nat Biotechnol . 30 . 7 . 631–637 . July 2012 . 22781692 . 10.1038/nbt.2289 . 5210967 .
  34. Wang B, Wu C, Zhong Q, Ling L, Wu Z, Yu B, Gao X, Zeng H, Yang DH . Belantamab mafodotin for the treatment of multiple myeloma . Drugs of Today . 57 . 11 . 653–663 . November 2021. 34821879 . 10.1358/dot.2021.57.11.3319146 . 244418854 .
  35. von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Caremoli ER, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer Jr CE . Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer . N Engl J Med . 380 . 7 . 617–628 . February 2019 . 0516102 . 10.1056/NEJMoa1814017 . 54524410 . free .
  36. Godwin CD, Gale RP, Walter RB . Gemtuzumab ozogamicin in acute myeloid leukemia . Leukemia . 31 . 1855–1868 . June 2017 . 9 . 10.1038/leu.2017.187 . 28607471 . 33623791 .
  37. Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K . Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer . N Engl J Med . 380 . 8 . 741–751 . February 2019. 30786188 . 10.1056/NEJMoa1814213 . 73489970 . free .
  38. Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, Soma M, Okamoto H, Oitate M, Arakawa S, Hirai T, Atsumi R, Nakada T, Hayakawa I, Abe Y, Agatsuma T . DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1 . Clin Cancer Res . 22 . 20 . 5097–5108 . October 2016 . 27026201 . 10.1158/1078-0432.CCR-15-2822 . 12462981 . free .
  39. Nicolaou KC, Rigol S . The Role of Organic Synthesis in the Emergence and Development of Antibody-Drug Conjugates as Targeted Cancer Therapies . Angew Chem Int Ed Engl . 58 . 33 . 11206–11241 . August 2019 . 31012193 . 10.1002/anie.201903498 . 128362562 .
  40. Graversen JH, Svendsen P, Dagnæs-Hansen F, Dal J, Anton G, Etzerodt A, Petersen MD, Christensen PA, Møller HJ, Moestrup SK . Targeting the Hemoglobin Scavenger receptor CD163 in Macrophages Highly Increases the Anti-inflammatory Potency of Dexamethasone . Mol Ther . 20 . 8 . 1550–1558 . August 2012 . 22643864 . 10.1038/mt.2012.103 . 3412497 . 17457555 . free .
  41. Svendsen P, Graversen JH, Etzerodt A, Hager H, Røge R, Grønbæk H, Christensen EI, Møller HJ, Vilstrup H, Moestrup SK . Antibody-Directed Glucocorticoid Targeting to CD163 in M2-type Macrophages Attenuates Fructose-Induced Liver Inflammatory Changes . Mol Ther Methods Clin Dev . 4 . 50–61 . March 2017 . 28344991 . 10.1016/j.omtm.2016.11.004 . 5363319 . 18592917 . free .
  42. Kern JC, Dooney D, Zhang R, Liang L, Brandish PE, Cheng M, Feng G, Beck A, Bresson D, Firdos J, Gately D, Knudsen N, Manibusan A, Sun Y, Garbaccio RM . Novel Phosphate Modified Cathepsin B Linkers: Improving Aqueous Solubility and Enhancing Payload Scope of ADCs . Bioconjug Chem . 27 . 9 . 2081–2088 . September 2016 . 27469406 . 10.1021/acs.bioconjchem.6b00337 .
  43. Brandish PE, Palmieri A, Antonenko S, Beaumont M, Benso L, Cancilla M, Cheng M, Fayadat-Dilman L, Feng G, Figueroa I, Firdos J, Garbaccio R, Garvin-Queen L, Gately D, Geda P, Haines C, Hseih S, Hodges D, Kern J, Knudsen N, Kwasnjuk K, Liang L, Ma H, Manibusan A, Miller PL, Moy LY, Qu Y, Shah S, Shin JS, Stivers P, Sun Y, Tomazela D, Woo HC, Zaller D, Zhang S, Zhang Y, Zielstorff M . Development of Anti-CD74 Antibody-Drug Conjugates to Target Glucocorticoids to Immune Cells . Bioconjug Chem . 29 . 7 . 2357–2369 . July 2018 . 29923706 . 10.1021/acs.bioconjchem.8b00312 . 49310298 .
  44. Han A, Olsen O, D'Souza C, Shan J, Zhao F, Yanolatos J, Hovhannisyan Z, Haxhinasto S, Delfino F, Olson W . Development of Novel Glucocorticoids for Use in Antibody-Drug Conjugates for the Treatment of Inflammatory Diseases . J Med Chem . 64 . 16 . 11958–11971 . August 2021 . 34378927 . 10.1021/acs.jmedchem.1c00541 . 236976999 .
  45. Hobson AD, McPherson MJ, Waegell W, Goess CA, Stoffel RH, Li X, Zhou J, Wang Z, Yu Y, Hernandez Jr A, Bryant SH, Mathieu SL, Bischoff AK, Fitzgibbons J, Pawlikowska M, Puthenveetil S, Santora LC, Wang L, Wang L, Marvin CC, Hayes ME, Shrestha A, Sarris KA, Li B . Design and Development of Glucocorticoid Receptor Modulator Agonists as Immunology Antibody-Drug Conjugate (iADC) Payloads . J Med Chem . February 2022 . 65 . 6 . 4500–4533 . 10.1021/acs.jmedchem.1c02099 . 35133822 . 246679075 .
  46. Yarian F, Alibakhshi A, Eyvazi S, Arezumand R, Ahangarzadeh S . Antibody-drug therapeutic conjugates: Potential of antibody-siRNAs in cancer therapy . J Cell Physiol . 234 . 10 . 16724–16738 . August 2019. 30908646 . 10.1002/jcp.28490 . 85515264 .
  47. Beck A, Goetsch L, Dumontet C, Corvaïa N . Strategies and challenges for the next generation of antibody–drug conjugates . Nature Reviews. Drug Discovery . 16 . 5 . 315–337 . May 2017 . 28303026 . 10.1038/nrd.2016.268 . 22045270 .
  48. Kovtun YV, Goldmacher VS . Cell killing by antibody–drug conjugates . Cancer Letters . 255 . 2 . 232–40 . October 2007 . 17553616 . 10.1016/j.canlet.2007.04.010 .
  49. Bąchor R, Kluczyk A, Stefanowicz P, Szewczuk Z . New method of peptide cleavage based on Edman degradation . Molecular Diversity . 17 . 3 . 605–11 . August 2013 . 23690169 . 3713267 . 10.1007/s11030-013-9453-y .
  50. Lyon RP, Setter JR, Bovee TD, Doronina SO, Hunter JH, Anderson ME, Balasubramanian CL, Duniho SM, Leiske CI, Li F, Senter PD . 6 . Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody–drug conjugates . Nature Biotechnology . 32 . 10 . 1059–62 . October 2014 . 25194818 . 10.1038/nbt.2968 . 5415162 .
  51. Kolodych S, Koniev O, Baatarkhuu Z, Bonnefoy JY, Debaene F, Cianférani S, Van Dorsselaer A, Wagner A . 6 . CBTF: new amine-to-thiol coupling reagent for preparation of antibody conjugates with increased plasma stability . Bioconjugate Chemistry . 26 . 2 . 197–200 . February 2015 . 25614935 . 10.1021/bc500610g .
  52. Wulbrand C, Seidl C, Gaertner FC, Bruchertseifer F, Morgenstern A, Essler M, Senekowitsch-Schmidtke R . Alpha-particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenation . PLOS ONE . 8 . 5 . e64730 . 2013 . 23724085 . 3665541 . 10.1371/journal.pone.0064730 . 2013PLoSO...864730W . Multhoff G . free .
  53. Cardoso MM, Peça IN, Roque AC . Antibody-conjugated nanoparticles for therapeutic applications . Current Medicinal Chemistry . 19 . 19 . 3103–27 . 2012 . 22612698 . 10.2174/092986712800784667 . free . 38141058 . 10362/20689 .
  54. Dovgan I, Koniev O, Kolodych S, Wagner A . Antibody-Oligonucleotide Conjugates as Therapeutic, Imaging, and Detection Agents . Bioconjugate Chemistry . 30 . 10 . 2483–2501 . October 2019 . 31339691 . 10.1021/acs.bioconjchem.9b00306 . 198491258 .
  55. Deonarain MP, Yahioglu G . Current strategies for the discovery and bioconjugation of smaller, targetable drug conjugates tailored for solid tumor therapy . Expert Opin Drug Discov . 16 . 6 . 613–624 . June 2021. 33275475 . 10.1080/17460441.2021.1858050 . 227297067 .
  56. Li Q, Barrett A, Vijayakrishnan B, Tiberghien A, Beard R, Rickert KW, Allen KL, Christie RJ, Marelli M, Harper J, Howard P, Wu H, Dall'Acqua WF, Tsui P, Gao C, Borrok MJ . Improved Inhibition of Tumor Growth by Diabody-Drug Conjugates via Half-Life Extension . Bioconjug Chem . 30 . 4 . 1232–1243 . April 2019 . 30912649 . 10.1021/acs.bioconjchem.9b00170 . 85517465 .
  57. Hwang D, Rader C . Site-Specific Antibody-Drug Conjugates in Triple Variable Domain Fab Format . Biomolecules . 10 . 5 . 764 . May 2020. 32422893 . 10.3390/biom10050764 . 7278019 . free .
  58. Aubrey N, Allard-Vannier E, Martin C, Bryden F, Letast S, Colas C, Lakhrif Z, Collinet N, Dimier-Poisson I, Chourpa I, Viaud-Massuard MC, Joubert N . Site-Specific Conjugation of Auristatins onto Engineered scFv Using Second Generation Maleimide to Target HER2-positive Breast Cancer in Vitro . Bioconjug Chem . 29 . 11 . 3516–3521 . November 2018. 30352511 . 10.1021/acs.bioconjchem.8b00668 . 53027552 .
  59. Hurov K, Lahdenranta J, Upadhyaya P, Haines E, Cohen H, Repash E, Kanakia D, Ma J, Kristensson J, You F, Campbell C, Witty D, Kelly M, Blakemore S, Jeffrey P, McDonnell K, Brandish P, Keen N . BT7480, a novel fully synthetic Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™) induces tumor localized CD137 agonism . J Immunother Cancer . 9 . 11 . e002883 . November 2021. 34725211 . 10.1136/jitc-2021-002883 . 8562524 . 240422681 . free .
  60. Axup JY, Bajjuri KM, Ritland M, Hutchins BM, Kim CH, Kazane SA, Halder R, Forsyth JS, Santidrian AF, Stafin K, Lu Y, Tran H, Seller AJ, Biroc SL, Szydlik A, Pinkstaff JK, Tian F, Sinha SC, Felding-Habermann B, Smider VV, Schultz PG . 6 . Synthesis of site-specific antibody–drug conjugates using unnatural amino acids . Proceedings of the National Academy of Sciences of the United States of America . 109 . 40 . 16101–6 . October 2012 . 22988081 . 3479532 . 10.1073/pnas.1211023109 . 2012PNAS..10916101A . free .
  61. Zawada JF, Yin G, Steiner AR, Yang J, Naresh A, Roy SM, Gold DS, Heinsohn HG, Murray CJ . 6 . Microscale to manufacturing scale-up of cell-free cytokine production--a new approach for shortening protein production development timelines . Biotechnology and Bioengineering . 108 . 7 . 1570–8 . July 2011 . 21337337 . 3128707 . 10.1002/bit.23103 .
  62. Flygare JA, Pillow TH, Aristoff P . Antibody–drug conjugates for the treatment of cancer . Chemical Biology & Drug Design . 81 . 1 . 113–21 . January 2013 . 23253133 . 10.1111/cbdd.12085 . 20523083 .
  63. Lehar SM, Pillow T, Xu M, Staben L, Kajihara KK, Vandlen R, DePalatis L, Raab H, Hazenbos WL, Morisaki JH, Kim J, Park S, Darwish M, Lee BC, Hernandez H, Loyet KM, Lupardus P, Fong R, Yan D, Chalouni C, Luis E, Khalfin Y, Plise E, Cheong J, Lyssikatos JP, Strandh M, Koefoed K, Andersen PS, Flygare JA, Wah Tan M, Brown EJ, Mariathasan S . 6 . Novel antibody-antibiotic conjugate eliminates intracellular S. aureus . Nature . 527 . 7578 . 323–8 . November 2015 . 26536114 . 10.1038/nature16057 . 2015Natur.527..323L . 205246581 .
  64. Web site: Ambrx Collaborates with Merck to Design and Develop Biologic Drug Conjugates . Press Release . dead . https://web.archive.org/web/20130107114403/http://ambrx.com/about-ambrx/06-18-2012.aspx . 2013-01-07 .
  65. Book: McPherson MJ, Hobson AD . Pushing the Envelope: Advancement of ADCs Outside of Oncology. Antibody-Drug Conjugates. Methods Mol Biol . 2020 . 31643047 . 10.1007/978-1-4939-9929-3_2 . 2078 . 23 . 23–36. 978-1-4939-9928-6. 204849993.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Antibody–drug conjugate".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.